Zimbabwe has rejected a substantial American health deal worth 367 million US dollars (£272m) spanning five years because of the United States' insistence on confidential biological samples.
This move became public after a official document dated December was disclosed, indicating that Head of State Emmerson Mnangagwa deemed the agreement was "skewed".
An official representative has since explained that the United States was seeking biological samples for scientific study and commercial gain while was not willing to guarantee the resulting advantages from future treatments.
"We must now begin the challenging and unfortunate process of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has appealed for continued dialogue to find a deal agreeable to both sides so the country's vital HIV programme can proceed.
Broader Context
This rejection comes after a comparable case in Kenya, where a high court halted a similar deal with the US after legal challenges were raised about the security of Kenyans' health data.
After resuming office recently, US President Donald Trump has reduced foreign aid and closed the key foreign aid agency.
The agency had administered assistance for the US government, but Trump argued its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
As per reports, Sixteen African countries have to date agreed to these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Rejected Deal
The funds for Zimbabwe would have gone towards "combating HIV/Aids, tuberculosis, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this partnership could have provided extraordinary benefits for Zimbabwean communities, particularly the 1.2 million men, women and children presently receiving antiretroviral therapy via US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information indefinitely, without any corresponding assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," he stated.
"Put simply, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be accessible to our population if a future disease outbreak emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its pursuit of one-on-one deals were undermining systems already set up via the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This mechanism is designed to guarantee that when a nation provides its information, the resulting advantages – including vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to develop them."
The government's concerns regarding the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We are open to further dialogue with our US partners on how future co-operation could be designed in a manner that honours the independence and interests of each country."
Health Experts Reaction
A leading public health body said it acknowledged the official position, but recommended that negotiations must proceed given that much of the country's HIV programmes depended on international support.
"Where technical issues exist, including those involving data governance or agreement terms, these can often be resolved via detailed discussion and negotiated safeguards," the group added.
This impasse highlights the ongoing debate between accepting vital international aid and safeguarding local interests in an ever more data-driven world.